This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
RSV researchers at major pharmaceuticalcompanies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceuticalcompanies are pushing to develop drugs and vaccines for RSV with these populations in mind.
But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.
One bright spot in an otherwise dreadful year: the pharmaceutical industry has discovered it can do things it never dreamed possible. Anyone who proposed that a novel, deadly virus would spread, with a vaccine developed demonstrating 95% efficacy, and approved for patients in less than a year would have been scoffed at.
Like most pharma companies of its size, Pfizer has faced its fair share of controversy as one of the most well-known drugmakers in the world. Since the turn of the millennium, Pfizer has embarked on a series of mega-mergers, gobbling up Warner-Lambert in 2000, Pharmacia and Upjohn in 2002, Wyeth in 2009, and Medivation in 2016.
He was referring to his business’ share of misconduct related fines that, between 2009 and 2017, topped $342 billion across the US and Europe. It’s killing us.” As the sector looks to maintain its momentum, it must be wary that positive messaging and increased scrutiny does not end up as a recipe for a hard fall.
She says she is “truly amazed” about what the industry has achieved in such a short time when it comes to innovations, vaccines and treatments. Camilla has a well-recognised track record working with various multinational companies, including AstraZeneca, Novartis and Allergan. About the author.
It was once derided as the stuff of science fiction, but in recent years, biotechnology has emerged as an important growth area in pharmaceuticals. As understanding of biological systems has forged ahead, pharmaceuticalcompanies have made increasing use of biotechnology in discovering and manufacturing new medicines.
After the outbreak of any epidemic or pandemic, all the responsibilities come on the shoulders of pharmaceuticalcompanies. With unprecedented diseases lurking on the corner, pharmaceuticalcompanies, are now obligated to widen their conventional horizons and look for substitute practices in their drug development strategies.
The company expects to commence P-I clinical trials on metastatic and pediatric primary bone cancer patients. Other radiotherapies under the company's pipeline include Humalutin and Alpha37. The company is evaluating Iomab-B in a P-III clinical trial (SIERRA) in patients with relapsed or refractory acute myeloid leukemia (AML).
model is a holistic approach to incorporate the same strategy to life science and pharmaceuticalcompanies. A globally fast-growing, and largest pharmaceuticalcompany in the world was created through a merger between Pfizer and Pharmacia. Model: Inspired by the industry 4.0 model, the pharma 4.0 compared to 2015.
President Joe Biden asked Slaoui to step down as chief scientific adviser to the US COVID-19 vaccine initiative after the White House administration changed late last month and the former GlaxoSmithKline research chief wasted no time in finding a new project.
During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry. While production volumes have now fallen, future vaccine demand is hard to predict, as booster shots could be needed at any point to control emerging variants.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content